Should smokers be prioritised for the vaccine?


Should smokers be prioritised for a Covid-19 vaccine? Several American states have decided that they should be. In Massachusetts, New Jersey, Mississippi, Pennsylvania and Virginia, they can receive the vaccine ahead of low-risk groups.

“The goal is to get people at greatest risk,” said Jennifer Tolbert, director of state health reform at the California-based Kaiser Family Foundation. “By targeting those individuals, you can hopefully reduce the chance of them ending up in the hospital with more severe cases of COVID and at greater risk of dying.”

“The coronavirus is a respiratory disease, so a smoker is at higher risk,” says Dr Albert Rizzo, of the American Lung Association. “We know that smoking causes inflammation of the airways. When the virus affects us, it causes inflammation as well. Vaccinating smokers will help stem the tide of more and more people being hospitalized and help prevent the health-care system from being overwhelmed.”

But to many people this seems odd, if not unfair. Aren’t smokers being rewarded for not taking care of their health?

In an interview in the Bill of Health blog, the director of Harvard’s Petrie-Flom Center, Carmel Shachar, explains that smoking “smoking is often the result of structural and biological factors that make it more prevalent in historically marginalized communities, and that denying priority access for smokers would reinforce existing inequities”.

What about the argument that smoking is a matter of choice?

Echoing the arguments of critical race theorists, Dr Shachar contends that this would burden “the health of communities of color and lower socioeconomic communities. There’s an equity argument to acknowledge that not everybody grows up in a community that is supportive of avoiding smoking and avoiding the peer pressure that leads to it, and that hasn’t been targeted as aggressively by advertisements to encourage people to smoke.”

Michael Cook is editor of BioEdge  




MORE ON THESE TOPICS |


This article is published by Michael Cook and BioEdge under a Creative Commons licence. You may republish it or translate it free of charge with attribution for non-commercial purposes following these guidelines. If you teach at a university we ask that your department make a donation. Commercial media must contact us for permission and fees. Some articles on this site are published under different terms.

 
 Search BioEdge

 Subscribe to BioEdge newsletter
rss Subscribe to BioEdge RSS feed

 
comments powered by Disqus